SPARTA Biodiscovery is a company commercializing the SPARTA® technology, which enables the accurate chemical analysis of nanoparticles in nanoformulations for next-generation therapeutics.

SPARTA Biodiscovery

SPARTA Biodiscovery is a brand-new spin-out company from Imperial College London developing and commercialising the SPARTA® technology. SPARTA® (Single Particle Automated Raman Trapping Analysis) is a breakthrough analytical technology for automated, label-free comprehensive characterisation of nanoformulations. SPARTA® is available through our service offering and in the near future as a benchtop instrument.

We welcome two great new team members this month! Ashkan Roozbeh has joined us as Senior Optical Engineer and Callum Macdonald as Software Engineer! #team!

What a start to the new year! Our co-founder Molly Stevens has been awarded a Damehood in the New Year Honours! https://lnkd.in/eVcPQqAg 
Congratulations Professor Dame Molly Stevens!

How can we use #nanotechnology to tackle antibiotic resistance? One approach is to use nanoparticles as reaction chambers, or #nanoreactors, to convert products released by bacteria into bactericidal agents to locally kill bacteria cells.
Michael Potter, PhD, Molly Stevens and team carefully designed semi-permeable nanoreactors loaded with antimicrobial enzymes to convert glucose into hypochlorite, a potent antimicrobial.
#SPARTA was used to demonstrate the semi-permeability of their nanoreactors on the single particle scale, as well as for detailed characterisation of the carrier chemistry.
Read more here! https://lnkd.in/etF2t7B8

Loading your small molecule API into a lipid delivery system is a challenge.  How does your molecule’s chemistry affect how it loads into #nanoparticles?
#SPARTA looks at the chemical profile of individual nanoparticles, in a rapid, automated, label-free manner, to tell you precisely how heterogeneously your cargoes are loading.
Check out how this has been shown in liposomes and polymer vesicles, including for the commercial #nanoformulation Doxil. #analytics

https://lnkd.in/gjRhJN_8

You spent years finding the right target. Do you have the optimal vector? 

LNP's as a vector have emerged as a leading platform. But, what gives you confidence your proprietary lipid composition or targeting ligand density is well known or characterized? 

#SPARTA can provide unparalleled insight into your formulation's composition in a rapid and automated format down to the single particle level. #nanoformulations #analytics 
https://lnkd.in/epgdJtzG

Join our CEO Jelle Penders speaking today at the 20th Anniversary #bioProcessUK conference of the BioIndustry Association (BIA) at the Next Generation Analytics session to learn how #SPARTA is Enabling #Nanoformulations for Next-Generation Therapeutics!

How well do you know your #nanomedicine? SPARTA looks the individual particle level in an automated and label-free way with minimal sample prep. Learn more today about how #SPARTA can bring you valuable insights!
https://lnkd.in/eVV2VS_n #nanoformulations #analytics

Our co-founder Molly Stevens was recently interviewed by Drug Discovery World! Read the article to find out more about her career highlights and how SPARTA fulfills an unmet need in drug delivery platform development. #nanoformulations #analytics

msh id	COM:SPARTABIODISCOVERY
symbol	-
name	SPARTA Biodiscovery
homepage url	https://spartabiodiscovery.com
country	GB
sector	Healthcare
industry	Biotechnology
market	PRIVATE
employee count	6
crunchbase url	https://www.crunchbase.com/organization/sparta-biodiscovery
linkedin url	https://www.linkedin.com/company/sparta-biodiscovery
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	54.44
growth score 28	54.94
growth score 90	50.62
growth score 365	28.18

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

COM:SPARTABIODISCOVERY

SPARTA Biodiscovery

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-